Pending Drug Applications To Be Poussot’s Top Priority As Wyeth’s New CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm announces third quarter pharmaceutical earnings of $4.7 billion, up 10 percent year-over-year.